Early Salvage Radiotherapy Recommended for Patients With Prostate Cancer Post-prostatectomy

Share this content:
Men with prostate cancer may benefit from early salvage radiotherapy (SRT) post-prostatectomy, regardless of whether prostate-specific antigen (PSA) levels are elevated.
Men with prostate cancer may benefit from early salvage radiotherapy (SRT) post-prostatectomy, regardless of whether prostate-specific antigen (PSA) levels are elevated.

Men with prostate cancer may benefit from early salvage radiotherapy (SRT) post-prostatectomy, regardless of whether prostate-specific antigen (PSA) levels are elevated, according to a study published in the Journal of Clinical Oncology.1

Researchers enrolled 1106 patients who received SRT between 1987 and 2013; median follow-up was 8.9 years. Evaluated variables included overall survival (OS), cumulative incidence for biochemical recurrence (BcR), distant metastases (DM), and cause-specific mortality (CSM).

Using multiple statistical analyses, it was determined that pre-SRT PSA were linked to each recorded variable; the relative risk of BcR, CSM, and all-cause mortality doubled with each pre-SRT PSA.

RELATED: Laproscopic and Open Prostatectomy Yield Similar 12-week Functional Outcomes

The authors conclude that clinicians ought not to monitor PSA levels post-prostatectomy before initiating SRT. Using SRT when PSA levels are low may reduce BcR, DM, CSM, and all-cause mortality.

Reference

  1. Stish BJ, Pisansky TM, Harmsen WS, et al. Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol. 2016 Aug 1. doi: 10.1200/JCO.2016.68.3425 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters